Post on 30-Jan-2021
Genesis, 01 December 2016
Case Study DealF-star / Denali
Jane Dancer, CBO
F-star Biotechnology Ltd
Company Highlights
Vision Team Platform Pipeline Partners
To dominate the bispecific antibody space in immuno-oncology through unique pipelinedepth and breadth
Leadership team has built numerous successful biotech companies and is backed by world-class scientific advisers
Highly efficient Modular Antibody Technology to rapidly identify First-in-Class products with novel biology
Deep proprietary immuno-oncology pipeline
Strong partnerships with top tier pharma partners including AbbVie, BMS (programme in Phase I), Merck and Denali Therapeutics with multiple additional partnering opportunities
2
The Most Powerful Approach to Create a Bispecific mAb
Permissive CH3 domain loop residues identified
Fc
Unparalleled versatility
Fcab ™
mAb² ™
Limited number of amino acid
substitutions required
CD
EF
AB
R D E L T K N Q V S
N G Q P E N N Y
D K S R W Q Q G N V
WT FcStructural integrity
and effectorfunctions retained
Introduction of an antigen binding site
with Fab potency (affinity, etc.)
Phage display libraries
Yeast display library
Plug-and-play insertion of Fcab into any mAb
LOOKS LIKE a mAb
Comparable structure
PERFORMS BEYOND a mAb
Synergy through bispecificity
WORKS LIKE a mAb
Retains antibody functionality
BEHAVES LIKE a mAb
Maintains CMC characteristics
COMBINATORIAL SCREENING
Easy mAb2 design & screening
Unrivalled speed in testing for novel biology
The Most Powerful Approach to Create a Bispecific mAb
Unparalleled versatility
Fcab ™
mAb² ™Virtually limitless
possibilities
Significant Expansion of Pipeline
5
FS118IND Filing 2017
FS18 FS17
FS20 FS22
FS101 FS117
AbbVie
Denali
Immuno-oncology
CNS disorders
Proprietary Partnered
BMSOncology (FS102)
Merck (EMD Serono)
Undisclosed
Denali Therapeutics: Key Facts
6
Parkinson’s disease
Alzheimer’s disease
ALS
Other neurodegenerative diseases
FOUNDED BY WORLD CLASS TALENT IN CNS DISORDERS
Alexander Schuth, COOex-Genentech,Merrill Lynch’s investment bank
Ryan Watts, CEO, Presidentex-Genentech - Head of Neuroscience
Marc Tessier-Lavigne, ex-Genentech - Head of ResearchRockefeller UniversityStanford University
$130mAUG 2016
SERIES B
$217mMAY 2014
SERIES A
Therapeutic bispecific
antibodies cross the blood-brain
barrier in nonhuman primatesNovember 2014
Delivery of Therapeutics across the Blood-Brain Barrier (BBB)
BBB
Brain
Blood SMALL MOLECULES
LARGER COMPOUNDS
TRANSPORTER
Fcab
Modular Antibody Technology™
mAb² mAb² mAb²
Potential to treat neurological diseases
Specific targets within the CNS
DENALI
Company Structure Provides Flexibility
SHAREHOLDERS SHAREHOLDERS SHAREHOLDERS SHAREHOLDERS
Asset Centric VehiclesPlatform Company
F-star GmbH
F-star BetaMULTIPLE IO ASSETS
F-star AlphaFS102
F-star GammaCNS DISORDERS
BMSOPTION TO BUY
IP / Services
F-starBiotechnology
AbbVieLICENCE
SHAREHOLDERS
F-star DeltaFUTURE ENTITIES
DenaliOPTION TO BUY
or LICENCE
$ $ $ $
Denali Deal Structure
9
COLLABORATION
Upfront payments: $6mResearch FundingTechnical Milestone PaymentsPre-specified number of Fcab targets
BUY-OUTTRACK
$450m in aggregate exercise and milestone payments
Y
LICENSINGTRACK
$1b potential aggregate value Pre-specified number
of mAb² based on each Fcab
N
Prior to the initiation Phase 1 clinical trial
OPTION EXERCISE